The EPO published European patent application EP3600345A1 for Cornell University's oxidation-resistant AAT gene therapy, with international patent classification spanning A61K (medicinal preparations), C07K (peptides), and C12N (microorganisms/genes). The application designates 33 EPC contracting states covering the EU, UK, Switzerland, Norway, and other European jurisdictions. Priority dates trace back to November 2020, indicating this represents a continuation or divisional of earlier filings.

Patent publications are informational filings that do not impose compliance obligations. Competitors developing AAT gene therapy products should review the claims to assess potential freedom-to-operate implications. The publication initiates a nine-month opposition period following patent grant. No action is required for parties not engaged in related technology development.